Alnylam Pharmaceuticals Stock News

Alnylam's (ALNY) portfolio of approved drugs is witnessing strong uptake so far while its pipeline is progressing well. However, stiff competition in the target market remains a woe.

Alnylam's (ALNY) earnings and sales fall shy of estimates in the first quarter of 2022. The company cuts 2022 guidance for net product revenues.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q1 2022 Earnings Conference Call April 28, 2022 8:30 AM ET Company Participants Christine Lindenboom - Senior Vice President of Investor Relations and Corp

Alnylam (ALNY) delivered earnings and revenue surprises of -3.63% and 12.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

The FDA needs time to review new information incorporated into Alnylam's (ALNY) vutrisiran NDA related to a new secondary packaging and labeling facility, which has been cited as a reason for the dela

Biotech stocks are very sensitive to some key catalysts such as the FDA decision date, aka PDUFA date, clinical readouts/presentations and Adcom meeting. The month of April will see some companies bel

The FDA has extended the review timeline for Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) marketing application for vutrisiran for transthyretin-mediated (ATTR) amyloidosis. The updated Prescripti

We think that Alnylam Pharmaceuticals stock, a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, currently is a better pick compared to Haemonetics (NYS

Tekla Healthcare Investors: A Dividend Paymaster That Can Compensate For Poor Price Performance

Alnylam: Suing Moderna, Pfizer Over LNP Technology. There May Be Method In This Madness

Alnylam Pharmaceuticals Inc said on Thursday it has separately filed lawsuits against Pfizer Inc and Moderna Inc, seeking damages for infringement of a patent in the manufacture and sale of their mRNA

Received FDA clearance of IND for TSC-100 for the treatment of hematologic malignancies Phase 1 umbrella trial for liquid tumor program to initiate in H1 2022; preliminary data expected in H2 2022 Two INDs for TSC-200 series anticipated by year end Strong balance sheet with cash and cash equivalents of $161.4 million as of December 31, 2021; funds Company into 2024 WALTHAM, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ: TCRX ), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today reported financial results for the full year ended December 31, 2021, and outlined key 2022 priorities. "As we had guided throughout 2021, in December we filed two INDs for our liquid tumor program. We also completed construction of our now fully functional 7,000 square-foot GMP manufacturing facility. Both of these steps are instrumental in our transformation to a clinical-stage company," said David Southwell, President and Chief Executive Officer. "We also advanced our growing pipeline of solid tumor candidates and look forward to sharing further details around these programs in the coming months." Recent Corporate Highlights In January 2022, the Company announced that the U.S.

Alnylam Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

DUBLIN--(BUSINESS WIRE)--The "RNA Interference (RNAi) Drug Delivery Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com''s offering. The global RNA interference (RNAi) drug delivery market reached a value of US$ 54.74 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 184.98 Billion by 2027, exhibiting a CAGR of 22.5% during 2022-2027. Companies Mentioned Alnylam Pharmaceuticals Inc.

The U.S. Food and Drug Administration ((FDA)) accepted Alnylam Pharmaceuticals (ALNY) supplemental New Drug Application ((sNDA)) seeking approval of OXLUMO (lumasiran) for reducing…